We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Hematologic Abnormalities Found in HIV-Infected Children

By LabMedica International staff writers
Posted on 22 Aug 2017
In both antiretroviral-treated and untreated individuals, different types of hematological abnormalities have been documented, the most important being pancytopenia. More...
These changes are related with increased risk of morbidity and mortality.

Anemia is a common finding in patients with human immunodeficiency viral (HIV) infection and it is more prevalent in patients with advanced retroviral infection. Its prevalence ranges from 11.7% to 92% depending on the stage of HIV disease, sex, age, pregnancy status, and presence of opportunistic infections (OIs).

Scientists at the University of Gondar (Ethiopia) conducted a cross-sectional study was conducted from June 1 to August 30, 2015 on 222 HIV-infected children. All children less than15 years of age who took antiretroviral therapy (ART) for more than six months were considered for inclusion in the study. Anemia, neutropenia and thrombocytopenia were defined based on World Health Organization (WHO, Geneva, Switzerland) grading of hematologic toxicity. Accordingly, anemia was defined as hemoglobin (Hgb) concentration equal to or less than 10.5 g/dL for all children and further severity was also classified. Neutropenia was defined as absolute neutrophil count (ANC) of less than 1,500/mm3, and any increased severity further classified.

The investigators reported that the median age of study subjects was 10 years and 74.3% of the study subjects received ART for more than a year. The median of CD4 count before ART was 490 cells/mm3 and this increased to 663 cells/ mm3 after ART. The median of hemoglobin before ART was 11.5 mg/dL which increased after ART to 13 mg/dL and the prevalence of anemia was 42.8% before and 18.9% after ART initiation. The median of absolute neutrophil count before ART was 3×103/mm3 and after ART remained practically almost unchanged. Thrombocytopenia was observed in 8.1% of the study patients and decreased to 1.8% after treatment with ARV drugs.

The authors concluded that anemia was the top abnormality identified, followed by thrombocytopenia and leukopenia and after ART initiation, and there was a significant improvement of the hematologic profile among the pediatric population studied. The study was published on August 4, 2017, in the Journal of Blood Medicine.

Related Links:
University of Gondar
World Health Organization


Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
HPV Molecular Test
BD Onclarity HPV Assay
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The approach supports myocardial infarction diagnosis in resource-limited settings by reducing delays between clinical suspicion and biochemical confirmation (Image Credit: Adobe Stock)

Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients

Timely confirmation of myocardial infarction often depends on laboratory testing that may not be immediately available at the point of care. This gap between clinical suspicion and definitive evidence... Read more

Molecular Diagnostics

view channel
Image: The platform analyzes cell-free DNA in blood, searching for minute amounts of tumor-derived fragments among background DNA (Image Credit: Adobe Stock)

Blood Test Could Help Fast-Track Lymphoma Diagnosis in Resource-Limited Settings

Lymphoma can be difficult to distinguish from infections and benign conditions, while definitive diagnosis often depends on surgical tissue sampling and specialized pathology that may not be readily available.... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.